Jefferies Flips to Buy as Chemed Shorts Retreat Post-Earnings

Chemed's pre-earnings short build has started to unwind. Jefferies upgraded CHE to Buy on Wednesday, raising its target 19% to $620 and pointing to a VITAS hospice rebound in 2026 and improving margins as the key drivers.

The upgrade lands one day after Chemed reported Q3 results. The stock rose 4.8% on October 28, its strongest single-day move in recent months, and is up 4.3% on the week. Among its closest healthcare peers, Ensign Group gained 6.2% over the same period, while UHS fell 5.8%. Addus HomeCare added 3.6%. CHE sits toward the top of the peer group on weekly performance, an about-turn from the pattern described in recent coverage.

The Short Build That Preceded the Print

Short interest climbed nearly 19% in the week before results, reaching 4.9% of the free float, the highest level in a month. That build has since begun to reverse. The current reading of 690,000 shares short is down slightly from the October 26 peak of 695,000 shares. At 23% above its one-month low, the position is still elevated, but the direction has shifted.

The borrow market carries no distress signals. Availability stands at over 5,000%, meaning shares available to lend vastly outnumber shares already borrowed. Cost to borrow sits at 0.41%, low by any standard, and has eased from the 0.50% touched earlier in the week.

Analyst Consensus Tightening Around Recovery

The Jefferies upgrade brings the analyst count to three Buy ratings against two Holds. The consensus price target stands at $592.60, against a current price of $533.36. UBS initiated with a Buy at $650 in September, and Oppenheimer maintained its Outperform with a $590 target in July.

The upgrade is a direct reversal of Jefferies' own January downgrade to Hold, when the same analyst cut the target to $475 citing VITAS headwinds. The firm now sees those headwinds easing. RBC Capital, which downgraded in February and raised its target to $548 in July, remains at Sector Perform.

Retail attention has also picked up sharply. An ORTEX alt data signal shows CHE's Wikipedia and ORTEX page-view activity running at a z-score of 6.0 against its own 90-day history as of October 21. That is a measure of attention, not a revenue indicator, but the spike coincides with the pre-earnings positioning shift.

What to Watch

The CEO sold 2,000 shares in both August and late September. Those sales are open-market transactions with no 10b5-1 plan disclosed, totalling just over $2.5m combined. They predate the post-earnings move and are worth tracking against future filings.

The level that would change the picture for short sellers is a sustained break of the 4.9% free float reading. If short interest continues to unwind from that peak and the stock holds its post-earnings gain, the pre-results bearish thesis will need fresh justification.

---

Data summary

• SI % of free float: 4.89%, down slightly from 4.93% one-day prior; up 18.7% on the week
• Cost to borrow: 0.41%, easing from 0.50% earlier this week
• Availability: 5,145%, lending market wide open
• Jefferies: upgraded to Buy, target raised to $620 from $520
• Consensus: 3 Buy, 2 Hold; mean target $592.60
• Stock: +4.76% on October 28, +4.3% on the week
• Next earnings: February 24, 2027